{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:14:44Z","timestamp":1778793284436,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI16C1074"],"award-info":[{"award-number":["HI16C1074"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C2014421"],"award-info":[{"award-number":["NRF-2021R1A2C2014421"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002582","name":"Gwangju Institute of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008422","name":"Genomics Research Institute, University of Pretoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bmc.2022.116862","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T20:26:01Z","timestamp":1654547161000},"page":"116862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation"],"prefix":"10.1016","volume":"68","author":[{"given":"Dongjae","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Ah","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanseok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunjae","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minji","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Gyoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5433-5071","authenticated-orcid":false,"given":"Jiwon","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.116862_b0005","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis; 2016. http:\/\/apps.who.int\/iris\/handle\/10665\/246177 (accessed 2021-10-26)."},{"key":"10.1016\/j.bmc.2022.116862_b0010","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2003.09.033","article-title":"Long-term safety of lamivudine treatment in patients with chronic hepatitis B","volume":"125","author":"Lok","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bmc.2022.116862_b0015","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2022.116862_b0020","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jhep.2019.02.006","article-title":"Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients","volume":"70","author":"Park","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2022.116862_b0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jhep.2013.11.022","article-title":"Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor","volume":"60","author":"Nkongolo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2022.116862_b0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41\u20134109 has multiple effects on hepatitis B virus capsid assembly","volume":"19","author":"Stray","year":"2006","journal-title":"J Mol Recognit"},{"key":"10.1016\/j.bmc.2022.116862_b0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jcv.2006.01.010","article-title":"Entecavir: a new treatment option for chronic hepatitis B","volume":"36","author":"Zoulim","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.bmc.2022.116862_b0040","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2022.116862_b0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon \u03b1-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepatitis"},{"key":"10.1016\/j.bmc.2022.116862_b0050","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0168-8278(01)00201-X","article-title":"Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B","volume":"35","author":"Tatulli","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2022.116862_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10200-5","article-title":"Ciclopirox inhibits hepatitis B virus secretion by blocking capsid assembly","volume":"10","author":"Kang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2022.116862_b0060","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bmc.2022.116862_b0065","doi-asserted-by":"crossref","first-page":"e3308","DOI":"10.1093\/cid\/ciaa807","article-title":"Entecavir plus pegylated interferon and sequential hepatitis B virus vaccination increases hepatitis B surface antigen seroclearance: a randomized controlled proof-of-concept study","volume":"73","author":"Lee","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmc.2022.116862_b0070","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"elife"},{"key":"10.1016\/j.bmc.2022.116862_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000291","article-title":"HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID\/Alb-uPA mice","volume":"5","author":"Joyce","year":"2009","journal-title":"PLoS pathog"},{"key":"10.1016\/j.bmc.2022.116862_b0080","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.4049\/jimmunol.181.7.4926","article-title":"Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner","volume":"181","author":"Lan","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2022.116862_b0085","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000360948","article-title":"Inhibitors of hepatitis B virus attachment and entry","volume":"57","author":"Lempp","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.bmc.2022.116862_b0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.gastro.2014.04.030","article-title":"Strategies to inhibit entry of HBV and HDV into hepatocytes","volume":"147","author":"Urban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bmc.2022.116862_b0095","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/mp300453k","article-title":"Structure\u2013activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP)","volume":"10","author":"Dong","year":"2013","journal-title":"Mol Pharmaceut"},{"key":"10.1016\/j.bmc.2022.116862_b0100","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00928431","article-title":"Cyclosporin A and C","volume":"3","author":"Dreyfuss","year":"1976","journal-title":"E J Appl Microbiol"},{"key":"10.1016\/j.bmc.2022.116862_b0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hlca.19870700103","article-title":"2. Neue cyclosporine aus Tolypocladium inflatum. Die cyclosporine K-Z","volume":"70","author":"Traber","year":"1987","journal-title":"Helv Chim Acta"},{"key":"10.1016\/j.bmc.2022.116862_b0110","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/hep.26982","article-title":"Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)","volume":"59","author":"Watashi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2022.116862_b0115","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jhep.2016.11.009","article-title":"Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity","volume":"66","author":"Shimura","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2022.116862_b0120","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1021\/acs.jmedchem.0c01484","article-title":"Potent and specific inhibition of NTCP-mediated HBV\/HDV infection and substrate transporting by a novel, oral-available cyclosporine A analogue","volume":"64","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0125","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bbrc.2013.12.052","article-title":"Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP","volume":"443","author":"Iwamoto","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2022.116862_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217433","article-title":"The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice","volume":"14","author":"Gallay","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2022.116862_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134707","article-title":"The novel cyclophilin inhibitor CPI-431-32 concurrently blocks HCV and HIV-1 infections via a similar mechanism of action","volume":"10","author":"Gallay","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2022.116862_b0140","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2022.116862_b0145","unstructured":"Hepion Pharmaceuticals, Inc., (2019, July 9 \u2013 2020, September 30), A Study in Healthy Volunteers. Identifier NCT03596697, https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03596697 (accessed 2021-12-01)."},{"key":"10.1016\/j.bmc.2022.116862_b0150","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1021\/jm500223x","article-title":"From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds","volume":"57","author":"Sweeney","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0155","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1021\/acs.orglett.9b01245","article-title":"Site selective amide reduction of cyclosporine A enables diverse derivation of an important cyclic peptide","volume":"21","author":"Peruzzi","year":"2019","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2022.116862_b0160","doi-asserted-by":"crossref","first-page":"8272","DOI":"10.1021\/acs.jmedchem.1c00211","article-title":"Interplay among conformation, intramolecular hydrogen bonds, and chameleonicity in the membrane permeability and cyclophilin A binding of macrocyclic peptide cyclosporin O derivatives","volume":"64","author":"Lee","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0165","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1021\/jo991687c","article-title":"Total synthesis of cyclosporin O both in solution and in the solid phase using novel thiazolium-, immonium-, and pyridinium-type coupling reagents: BEMT, BDMP, and BEP1","volume":"65","author":"Li","year":"2000","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0170","doi-asserted-by":"crossref","first-page":"10646","DOI":"10.1021\/ja00052a076","article-title":"Efficient method for the preparation of peptoids [oligo (N-substituted glycines)] by submonomer solid-phase synthesis","volume":"114","author":"Zuckermann","year":"1992","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2022.116862_b0175","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nchembio.1580","article-title":"Comprehensive analysis of loops at protein-protein interfaces for macrocycle design","volume":"10","author":"Gavenonis","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2022.116862_b0180","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1021\/acs.jmedchem.6b01246","article-title":"Passive membrane permeability in cyclic peptomer scaffolds is robust to extensive variation in side chain functionality and backbone geometry","volume":"59","author":"Furukawa","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0185","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/acs.jmedchem.6b01483","article-title":"Nonclassical size dependence of permeation defines bounds for passive adsorption of large drug molecules","volume":"60","author":"Pye","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0190","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4155\/fmc.15.78","article-title":"Beyond cyclosporine A: conformation-dependent passive membrane permeabilities of cyclic peptide natural products","volume":"7","author":"Ahlbach","year":"2015","journal-title":"Fut Med Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0195","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1039\/C2MD20203D","article-title":"Optimizing PK properties of cyclic peptides: the effect of side chain substitutions on permeability and clearance","volume":"3","author":"Rand","year":"2012","journal-title":"MedChemComm"},{"key":"10.1016\/j.bmc.2022.116862_b0200","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1021\/ja0668623","article-title":"Quantitative evaluation of the relative cell permeability of peptoids and peptides","volume":"129","author":"Kwon","year":"2007","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2022.116862_b0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/anie.200904529","article-title":"A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins","volume":"49","author":"Male\u0161evi\u0107","year":"2010","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2022.116862_b0210","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1021\/jm4007577","article-title":"Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147","volume":"56","author":"Malesevic","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116862_b0215","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4196\/kjpp.2011.15.5.291","article-title":"Inhibitory actions of HERG currents by the immunosuppressant drug cyclosporin A","volume":"15","author":"Lee","year":"2011","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.bmc.2022.116862_b0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1248\/yakushi.127.209","article-title":"Effect of cyclosporine and tacrolimus on cytochrome P450 activities in human liver microsomes","volume":"127","author":"Niwa","year":"2007","journal-title":"Yakugaku Zasshi"},{"key":"10.1016\/j.bmc.2022.116862_b0225","article-title":"Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS ONE"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622002541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622002541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:50:26Z","timestamp":1778791826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622002541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":45,"alternative-id":["S0968089622002541"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116862","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116862"}}